Whoop, the screenless fitness-tracking strap best known for turning heart rate variability and sleep data into daily “recovery” scores, announced on August 18, 2026 that it is opening its Advanced Labs testing service to anyone, not just paying members, and adding GRAIL’s Galleri multi-cancer early detection test to the lineup. It is a striking pivot for a company that built its business on wearable sensors: the newest addition to its platform doesn’t come from a wristband at all, but from a single blood draw.
From Recovery Scores to Blood Panels
Whoop Advanced Labs combines comprehensive blood testing, clinician-reviewed results and AI-generated insights covering cardiovascular, metabolic, hormonal and inflammatory health, delivered through the same app that already tracks a user’s strain and sleep. Blood is drawn at roughly 2,000 Quest Diagnostics locations around the U.S., and results, including the new Galleri screen, arrive inside the Whoop app alongside educational material meant to help people interpret what a given result means and whether it warrants a follow-up conversation with a clinician. Until this announcement, the service required a Whoop hardware subscription; now anyone can pay for Advanced Labs on its own, an acknowledgment that the real value Whoop is chasing may be diagnostic, not just behavioral.
What Galleri Actually Detects
Galleri, made by the Illumina spinout GRAIL, screens a single blood sample for molecular signals associated with more than 50 types of cancer and attempts to estimate where in the body a detected signal originates. GRAIL runs the test out of its own laboratory in North Carolina and lists it directly at $949; Whoop has not disclosed its own pricing for the integration. The test targets adults 50 and older at elevated cancer risk, and it is explicitly meant to supplement, not replace, existing screening like mammograms, colonoscopies and lung and cervical cancer checks.
The Accuracy Numbers Are More Complicated Than the Marketing
Independent data on Galleri’s performance complicates the pitch of a single blood draw catching cancer early. In GRAIL’s PATHFINDER 2 study, designed to mirror real-world screening use, Galleri detected an overall cancer signal in only about 40.4% of cases. For twelve cancers responsible for roughly two-thirds of U.S. cancer deaths, sensitivity rose to 73.7% — a meaningfully better number, but still one that misses roughly a quarter of cases. Early-stage detection, arguably the entire point of a screening test, has run as low as 16.8% in earlier research. The test’s false-positive rate is low, around 0.4%, but among people who do get a positive signal, cancer is confirmed only about 61.6% of the time, meaning a substantial share of flagged results turn out to be false alarms that still trigger costly, anxiety-inducing follow-up imaging and biopsies. Galleri is also not yet FDA-approved; it operates under CLIA lab-developed test rules, and GRAIL’s premarket approval application is scheduled for an FDA advisory panel review on September 23, 2026 — just weeks after Whoop’s announcement.
Why a Fitness Wearable Wants to Be a Health Platform
Whoop’s move fits a broader pattern of consumer wearable companies racing to become health platforms rather than single-purpose trackers. The company has separately rolled out an AI coaching feature called Whoop Coach and “Advanced Labs” style integrations with services like Natural Cycles for reproductive health, layering AI-generated interpretation on top of every new data stream it adds. Whoop’s valuation has reportedly crested $10 billion, and the company is in hiring mode, having announced plans in early 2026 to add more than 600 roles. Bundling a cancer-detection test into an app already checked daily by millions of members is, from a business standpoint, a low-cost way to deepen engagement and justify a subscription price increase — regardless of how the underlying science shakes out.
What to Watch Next
The September 23 FDA advisory panel meeting on Galleri will be the more consequential event for the technology itself, since an FDA approval (or a rejection or requested changes) will shape how confidently companies like Whoop can market the test to a general consumer audience going forward. In the meantime, physicians and screening researchers are likely to keep pushing back on framing an unapproved, moderate-sensitivity blood test as a fitness-app feature, worried that a clean-looking app interface can make a probabilistic, imperfect test feel more definitive than it is. Whoop, for its part, is betting that consumers increasingly want one app for everything from sleep debt to cancer risk — and that convenience, not caveats, is what will drive adoption.
Photo: Nutrisense Inc / PEXELS via Pexels
